The cheapest legitimate routes to GLP-1 medications in 2026 are manufacturer assistance programs (as low as $25/month for eligible commercially insured patients, or free for qualifying uninsured patients), competitive telehealth platforms ($199–$299/month), and Medicare Part D coverage for patients with documented cardiovascular risk. Wegovy's retail list price is $1,349/month — but most people paying that have not explored what is actually available to them.
Wegovy's retail price is $1,349 per month. Zepbound runs $1,059 to $1,349 depending on the dose. Those numbers appear in every news story about GLP-1 medications, and they are accurate — but they are also the wrong starting point for most people.
The standard framing goes like this: GLP-1 medications are either covered by your insurance, or they are a luxury drug. Google "how to afford Wegovy" and you get this narrative confirmed immediately, usually with the suggestion to "talk to your doctor about coverage." That is not wrong. It is just not nearly enough of an answer.
The mainstream advice was built for a simpler market. What has actually changed in 2026 is that the telehealth access channel has become intensely competitive, driving prices down significantly. Manufacturer assistance programs that most eligible patients never apply for exist at both Novo Nordisk and Eli Lilly. And Medicare — which explicitly excluded weight-loss drugs for decades — now covers Wegovy for a specific cardiovascular indication, following the SELECT trial results showing a 20% reduction in major cardiovascular events.
The cheapest route of 2024 — compounded semaglutide from a 503A pharmacy at $150 to $200 per month — is largely closed off now. The FDA resolved the semaglutide shortage in October 2024, and 503A compounding pharmacies were required to stop dispensing it by March 2025. That changes the calculation. But the medication is not out of reach for most people who genuinely need it.
What GLP-1 Medications Actually Cost in 2026 — The Real Numbers
There are five GLP-1 receptor agonists widely prescribed in the US for metabolic health and weight management. They are not equally priced, and the indication — obesity versus type 2 diabetes — changes both coverage rules and pricing architecture.
| Medication | Manufacturer | Primary Indication | Retail Price/Month |
|---|---|---|---|
| Wegovy (semaglutide 2.4mg) | Novo Nordisk | Obesity (BMI ≥30) | ~$1,349 |
| Zepbound (tirzepatide) | Eli Lilly | Obesity (BMI ≥30) | $1,059–$1,349 |
| Ozempic (semaglutide 1mg) | Novo Nordisk | Type 2 diabetes | ~$935 |
| Mounjaro (tirzepatide) | Eli Lilly | Type 2 diabetes | ~$1,000 |
| Rybelsus (oral semaglutide) | Novo Nordisk | Type 2 diabetes | ~$870 |
The diabetes-indicated versions — Ozempic and Mounjaro — are frequently prescribed off-label for weight management, which is why their prices appear alongside the obesity-indicated drugs. The chemistry is often identical or closely related; the indication changes the coverage rules, not the underlying molecule.
These are list prices. Very few people pay them consistently. Understanding where you start matters for knowing how far down you can get — and by which route.
Telehealth Platforms: The Most Accessible Route
The telehealth GLP-1 market in 2026 looks different from what it was in 2023. When compounded semaglutide was freely available, platforms competed primarily on compound pricing. With semaglutide compounding largely restricted after the shortage resolution, competition has shifted to who can arrange the best access to brand medications at the lowest direct-pay price.
The question I hear most often: are these platforms actually cheaper, or are they charging a platform fee on top of regular pharmacy prices? In most cases, these companies are negotiating volume arrangements that individual patients cannot access independently. The net cost — platform membership plus medication — typically lands below what retail pricing plus a standard insurance specialty copay would produce. But verify for your specific situation before committing.
Hims & Hers Weight Loss Program
After building its early user base on compounded semaglutide, Hims pivoted to a brand drug access model in 2025. Brand Wegovy access through their program starts around $199/month in 2026. Prescriptions are issued through their clinical platform after a structured intake — you still need a licensed provider to approve you, which happens within the platform.
Ro Body
Ro charges a platform membership plus medication cost. Their pricing typically starts at $299–$399/month for the full program, including clinical intake and ongoing provider access. Their model is transparent about separating the membership fee from the drug cost, which makes it easier to compare against alternatives.
Found and Calibrate
Found and Calibrate operate more as structured metabolic health programs that include medication access, rather than pure prescription-delivery services. Monthly fees run $299–$500 and include nutrition coaching, accountability check-ins, and more structured follow-up. If the support structure is something you want alongside the medication, these platforms are worth considering — but they are not the cheapest option if you are looking for medication access alone.
One thing these platforms do not always make obvious: promotional pricing changes. The $199 introductory rate at one platform may become $349 in month four. Ask explicitly what you will pay at month 3, month 6, and month 12 before you sign up. The long-term commitment required for GLP-1 therapy makes this calculation important from day one.
Manufacturer Assistance Programs: The Most Underused Option
This is the option most people with legitimate need never pursue. Both Novo Nordisk and Eli Lilly run structured patient assistance programs, and the income thresholds are not as restrictive as most people assume.
A lot of people hear "patient assistance program" and picture paperwork designed to discourage use. The reality is different. These programs exist because manufacturers need real-world patient data, they want broad demographic reach for their medications, and they benefit commercially from patients building long-term relationships with their drugs. The incentive structure favours you applying.
Novo Nordisk Programs (Wegovy and Ozempic)
WegovyAssist: for commercially insured patients who still face high out-of-pocket costs, this savings card caps monthly copays at $25. You apply at novocare.com or through your prescribing provider. Note: this applies to commercially insured patients only — not Medicare or Medicaid.
NovoCare Patient Assistance Program: for uninsured or underinsured patients below a certain income threshold, Wegovy can be provided at no cost. The threshold is higher than most people expect — verify your eligibility before assuming you do not qualify.
Eli Lilly Programs (Zepbound and Mounjaro)
Zepbound Savings Card: for commercially insured patients, this card saves up to $550 per month off the list price — potentially bringing the net monthly cost to under $600 even without strong insurance coverage.
Lilly Cares Foundation: for uninsured patients at or below 400% of the federal poverty line, Zepbound and Mounjaro may be provided at no cost. Applications are processed through lillycares.com or through your provider's office.
Insurance Coverage: When It Actually Works in 2026
Insurance coverage of GLP-1 medications remains inconsistent across the US market — but the landscape has shifted meaningfully since 2023. Understanding what changed and what remains variable saves you from either assuming you are covered when you are not, or assuming you are not covered when you might be.
Medicare
In 2024, CMS approved coverage of Wegovy under Medicare Part D for patients with documented cardiovascular disease or high cardiovascular risk, following the SELECT trial that demonstrated a 20% reduction in major cardiovascular events in this population. According to CMS guidance published in 2024, an estimated 3.6 million Medicare beneficiaries may qualify under this indication. This is not broad obesity coverage — you need to meet the cardiovascular criteria. But for patients who do, it is a significant change. Medicare still does not cover GLP-1 drugs for obesity alone.
Commercial Insurance
Coverage varies sharply by employer and plan. Some large employers restricted GLP-1 coverage after 2024 due to cost pressures. Others cover it fully under specialty drug tiers. The most common barrier is step therapy — your insurer may require documentation that you attempted other weight-loss interventions before approving a GLP-1. Ask your HR benefits team specifically: does our plan cover Wegovy or Zepbound under the obesity indication, or only under the diabetes indication? The answer changes what your prescriber needs to document.
Medicaid
Coverage is state-by-state. Coverage for the diabetes-indicated versions (Ozempic, Mounjaro) is more common than coverage for the obesity-indicated versions (Wegovy, Zepbound). Check your state's Medicaid drug formulary directly — it changes more frequently than most people realise.
GoodRx and Third-Party Discount Tools
GoodRx is more useful for some GLP-1s than others. The honest answer is that it provides moderate savings on the diabetes-indicated drugs, and more limited savings on the obesity-indicated versions.
For Ozempic and Mounjaro, GoodRx can reduce retail prices by 20–40% at participating pharmacies. That still leaves them expensive, but it is not nothing — on a $935 list price for Ozempic, a 35% reduction brings you to roughly $600 per month. For Wegovy and Zepbound, GoodRx discounts tend to be less dramatic, because Novo Nordisk and Eli Lilly control more of the pricing structure for their obesity-indicated products.
Mark Cuban's Cost Plus Drugs — the platform built around purchasing active pharmaceutical ingredients directly and passing savings to patients — does not currently carry brand GLP-1 medications. Their model requires generic equivalents or drugs where they can source the API independently. Novo Nordisk's patent on semaglutide runs through 2031 in most jurisdictions. If a generic semaglutide ever reaches the US market, Cost Plus would likely be among the cheapest distribution channels. That is not a 2026 option.
The Compounding Question: What Is Legal in 2026
This section needs a direct answer, because the information circulating online is often either outdated or misleading.
The FDA removed semaglutide from its drug shortage list in October 2024. Under federal compounding law, 503A pharmacies — the standard compounding pharmacies used by most patients — lost the legal basis to compound semaglutide shortly thereafter. The compliance deadline for 503A pharmacies was March 2025. 503B outsourcing facilities had until May 2025. According to FDA guidance on drug compounding, once a drug shortage is resolved, the shortage exemption that permitted compounding ceases to apply.
Compounded semaglutide from standard 503A pharmacies is not legally dispenses as a shortage exemption in the US as of 2026.The legal nuances that remain: pharmacies can still compound "personalised" formulations for patients with documented clinical needs that differ from commercially available options — for example, combining semaglutide with B12 or cyanocobalamin under a prescriber's specific clinical judgment. Whether these approaches withstand regulatory scrutiny is genuinely uncertain and has been contested in multiple legal proceedings in 2025 and 2026.
Tirzepatide was removed from the shortage list in December 2024, with similar timelines for the compounding wind-down following shortly after.
What this means practically: if you see a telehealth platform or pharmacy advertising straightforward compounded semaglutide for $150 per month in 2026, you are looking at either a regulatory grey area or a company operating outside current rules. The clinical and legal risk sits with you as the patient. That is not nothing to consider.
International pharmacies in Mexico and Canada operate outside FDA jurisdiction and may offer differently manufactured versions at substantially lower prices. Importing for personal use in small quantities is technically prohibited under federal law, though enforcement discretion at the customs level has historically been broad for personal quantities. This is an acknowledgment of what many people are doing — not a recommendation.
How to Build Your GLP-1 Access Strategy — Step by Step
The people who end up paying the most for GLP-1 medications are usually the ones who took the first option they found. The people who pay the least are the ones who ran the comparison. Here is the sequence that produces the best outcome most reliably.
Step 1: Confirm your diagnosis and indication
GLP-1 access programs and coverage rules depend on whether you qualify under the obesity indication (BMI ≥30, or BMI ≥27 with a weight-related comorbidity such as hypertension, sleep apnoea, or high cholesterol) or the type 2 diabetes indication. Get clarity on this with your prescriber before pursuing any specific cost pathway — because the pathway depends on the indication.
Step 2: Call your insurance before your prescriber submits anything
Ask specifically whether Wegovy, Zepbound, Ozempic, or Mounjaro are covered under your plan and at which formulary tier. Ask whether step therapy requirements apply. Ask what documentation the prior authorisation process requires. Get the coverage determination in writing. This call takes 15 minutes and can save you months of rejection-and-appeal cycles.
Step 3: Apply for the manufacturer savings program regardless of insurance status
Even if you have insurance, apply for the relevant savings card — WegovyAssist or the Zepbound Savings Card. In some situations, the cash price plus the savings card beats your insurance copay. The applications take less than 10 minutes. Your prescribing provider's office will often handle the submission as a matter of routine.
Step 4: Get quotes from two or three telehealth platforms
Get actual quotes, not advertised prices. Ask what you will pay in months 1, 3, and 6. Ask whether the price includes all fees — clinical intake, platform membership, and medication. Then compare the all-in annual cost against the best outcome from steps 2 and 3. The timeline for meaningful results on GLP-1 therapy typically runs 12 to 24 weeks to peak effect, which means you are committing to at least six months of cost.
Step 5: Calculate 12-month cost, not monthly cost
Optimising for month one and discovering in month four that a promotional rate has expired is a very common mistake. GLP-1 therapy is a long-term commitment for most patients — understanding the sustained nature of the treatment is part of making a responsible cost decision. Calculate the annualised total for each option you are comparing, including the likelihood of dose escalation (which changes the price on some formularies). Also consider your nutritional support costs alongside the medication — GLP-1 users often need deliberate protein and micronutrient supplementation that adds to the monthly total.
This is not a simple drug to access cheaply. The system was not designed with affordability as the primary value. But it was also not designed for the competitive telehealth market, the manufacturer programs, or the Medicare cardiovascular coverage expansion that now exist. The lowest accessible price in 2026 is meaningfully lower than it was in 2022 — if you know where to look and how to approach the comparison systematically. For a comprehensive overview of the health technology tools and programs that can support your metabolic health, the WiseGoodness Health Techs pillar covers the full landscape.
Frequently Asked Questions
Through manufacturer assistance programs, eligible patients can access Wegovy for $25/month via WegovyAssist, or at no cost through NovoCare for uninsured patients below the income threshold. For patients who do not qualify for assistance programs, telehealth platforms currently offer the lowest accessible prices at $199–$299/month for brand medications. Retail pricing without any assistance starts at around $870/month for Rybelsus and reaches $1,349/month for Wegovy.
Compounded semaglutide from standard 503A pharmacies is no longer legally available under shortage exemptions as of 2026, following the FDA's resolution of the semaglutide drug shortage in October 2024. 503A pharmacies had until March 2025 to stop dispensing it, and 503B outsourcing facilities until May 2025. Some grey areas remain around personalised formulations with documented clinical need, but any platform still advertising straightforward compounded semaglutide in 2026 should be verified carefully with your healthcare provider before you proceed.
As of 2024, Medicare Part D covers Wegovy for patients with documented cardiovascular disease or high cardiovascular risk — specifically those who meet criteria similar to the SELECT trial population. Medicare does not broadly cover GLP-1s for obesity alone. Coverage for the diabetes-indicated versions such as Ozempic and Mounjaro under Part D depends on your specific plan and formulary.
Novo Nordisk runs two programs. WegovyAssist is a savings card for commercially insured patients that caps monthly copays at $25. The NovoCare Patient Assistance Program is for uninsured or underinsured patients below certain income thresholds and provides Wegovy at no cost for eligible individuals. Applications are available at novocare.com or through your prescribing provider, and your provider's office can often complete the submission on your behalf.
Pricing changes frequently as platforms compete for market share. As of mid-2026, Hims & Hers has offered brand Wegovy access starting around $199/month, while Ro and Found tend to start higher at $299–$399/month. Always get a quote that includes all fees — platform, clinical intake, and medication — and ask what the price looks like at month 6, not just month 1. A lower headline price with a sharp escalation at month 3 is not actually cheaper.
Importing prescription medications for personal use from Canada or Mexico is technically prohibited under federal law, though the FDA has historically exercised enforcement discretion for small personal-use quantities. Prices in Mexico in particular can be substantially lower than US retail. The regulatory risk, variability in product quality, cold-chain integrity concerns, and absence of clinical oversight are real factors to weigh carefully before pursuing this route.
According to clinical trial data published in NEJM (2023), most of the weight lost during GLP-1 therapy returns within one to two years of stopping the medication. For most patients, this means ongoing therapy rather than a time-limited course — which makes the cost calculation over 3 to 5 years far more relevant than the monthly price alone. Factor that into your planning from the start, not after you have already made a commitment.
